Therapixel, a Nice, Paris-France- and Chicago, IL-based company focused on the design and commercialization of AI-powered medical imaging software, raised €15M in Series B funding.
The round was led by Crédit Mutuel Innovation and CapHorn, with participation from Verve, Sham Innovation Santé, Omnes, IT-Translation, M-Capital and Région Sud Investissement.
The company intends to use the funds to accelerate its commercial presence in the United States, and launch more features for MammoScreen.
Led by CEO Matthieu Leclerc-Chalvet, and Chief Scientific and Technology Officer and Founder Pierre Fillard, Therapixel is focused on the design and commercialization of AI-powered medical imaging software, with the goal of delivering pertinent information at the right time to healthcare professionals. The company has developed MammoScreen, a software system that helps with the interpretation of screening 2D and 3D mammograms.
Armed with two FDA regulatory clearances in the United Stated for both 2D and 3D (tomosynthesis) mammography, MammoScreen is already being deployed across large networks of breast cancer screening clinics. It uses a score to signal at a glance the level of suspicion of a mammogram. This makes it possible to confirm the lesions that are certain and to save precious time with a faster reading of benign cases.